CARsgen Therapeutics Holdings Ltd. has issued a profit alert indicating an estimated reduction in net loss for the first half of 2025. The company anticipates a net loss of not more than approximately RMB80 million for the reporting period ending June 30, 2025, significantly lower than the RMB351 million loss reported for the same period in 2024. Additionally, the adjusted net loss, which excludes share-based compensation, is projected to be no more than RMB75 million, down from RMB342 million in the previous year. This improvement is largely attributed to increased revenues from the commercialization of their product CT053 in mainland China and the acceptance of the New Drug Application for CT041 by the National Medical Products Administration. Investors are advised to exercise caution when dealing with the company's shares as the full financial results are expected to be published by the end of August 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.